跳至主要内容
临床试验/NCT03230630
NCT03230630已完成不适用

Early-morning Plasma Melatonin Levels Predict Cardiovascular Mortality After Acute Myocardial Infarction

Chinese PLA General Hospital0 个研究点目标入组 732 人开始时间: 2013年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
732
主要终点
cardiovascular mortality

研究概览

简要总结

Pre-clinical and clinical studies have demonstrated that melatonin has cardio-protection effects. Melatonin has anti-inflammatory, antioxidant, antihypertensive, antithrombotic and antilipaemic properties, which plays important roles in a variety of cardiovascular pathophysiologic processes. Nocturnal melatonin levels decreased after AMI, and lower serum melatonin concentrations after AMI are associated with more heart failure and cardiac death and left ventricular remodeling. Moreover in women with increased BMI, lower melatonin secretion is associated with higher risks of MI. Early-morning blood collection is easier in clinical practice. Therefore, the investigators carried out a cohort study to evaluate the prognostic value of plasma soluble melatonin in hospitalized patients with acute myocardial infarction (AMI).

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Other

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • consecutive patients of acute AMI come to department of cardiology, 301 hospital (Beijing, China),absent of cardiogenic shock, and survival for at least 24 h after percutaneous coronary intervention treatment.

排除标准

  • patients with autoimmune diseases, collagen tissue diseases, drug addiction, radiotherapy, patients receiving immunosuppressive treatment, taking sedatives, antiepileptic drugs, tricyclic antidepressants or any medication known to influence melatonin metabolism, psychiatric sleeping disorders, shift workers, and subjects with jet-lag syndrome

结局指标

主要结局

cardiovascular mortality

时间窗: The median follow-up was 31.6 months

次要结局

  • Stroke(The median follow-up was 31.6 months)
  • non-cardiovascular mortality(The median follow-up was 31.6 months)
  • Myocardial infarction(The median follow-up was 31.6 months)
  • heart failure readmission(The median follow-up was 31.6 months)

研究者

发起方
Chinese PLA General Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Li Jing Wei

Doctor

Chinese PLA General Hospital

相似试验